Valuation: Alvotech

Market Cap 2.1B 1.84B 1.74B 1.59B 2.97B 201B 2.99B 20.81B 8.07B 103B 7.88B 7.71B 333B P/E 2026 *
113x
P/E 2027 * 19.8x
Enterprise Value 3.18B 2.79B 2.63B 2.4B 4.49B 305B 4.53B 31.48B 12.21B 155B 11.92B 11.66B 504B EV / Sales 2026 *
4.82x
EV / Sales 2027 * 4.07x
Free-Float
39.95%
Yield 2026 *
-
Yield 2027 * -
1 day-0.51%
1 week+13.92%
Current month+11.95%
1 month+31.15%
3 months+57.03%
6 months+74.47%
Current year+13.26%
1 week 5.4
Extreme 5.395
6.06
1 month 4.78
Extreme 4.782
6.06
Current year 2.94
Extreme 2.94
6.06
1 year 2.94
Extreme 2.94
9.04
3 years 2.94
Extreme 2.94
18
5 years 2.94
Extreme 2.94
18
10 years 2.94
Extreme 2.94
18
Manager TitleAgeSince
Chief Executive Officer 55 2026-02-28
Director of Finance/CFO 48 2025-07-09
Chief Tech/Sci/R&D Officer - 2022-12-31
Director TitleAgeSince
Chairman 56 2018-12-31
Director/Board Member 64 2018-12-31
Director/Board Member 58 2018-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
4/1/26 Free

Chief Executive Officer

117,271 0.0355%
4/1/26 Sell

Founder

318,000 0.0963%
4/1/26 Buy

Founder

318,000 0.0963%
Change 5-day change 1-year change 3-year change Capi.($)
-0.51%+13.92%-33.22%-34.57% 2.07B
+1.46%+5.87%+5.75%+33.71% 47.56B
+2.67%+2.31%+47.50%+38.37% 44.09B
-1.38%+3.42%+9.39%+88.88% 41.5B
+4.78%+2.01%+352.12%+566.20% 40.88B
-0.62%+0.11%+1.12%+46.02% 29.67B
+0.56%+0.67%+25.08%+155.71% 17.23B
+2.05%+4.04%+24.47%+41.67% 15.06B
+3.39%-6.86% - - 14.65B
+7.38%+17.54%-2.25% - 13.82B
Average +0.85%+1.50%+47.78%+117.00% 26.65B
Weighted average by Cap. +0.93%+1.02%+71.01%+145.91%

Financials

2026 *2027 *
Net sales 659M 580M 546M 499M 932M 63.26B 940M 6.54B 2.53B 32.22B 2.48B 2.42B 105B 776M 682M 642M 587M 1.1B 74.42B 1.11B 7.69B 2.98B 37.91B 2.91B 2.85B 123B
Net income 30.36M 26.69M 25.14M 22.97M 42.93M 2.91B 43.3M 301M 117M 1.48B 114M 112M 4.82B 109M 95.9M 90.35M 82.56M 154M 10.47B 156M 1.08B 419M 5.33B 410M 401M 17.33B
Net Debt 1.08B 947M 892M 815M 1.52B 103B 1.54B 10.68B 4.14B 52.63B 4.04B 3.96B 171B 1.06B 929M 875M 800M 1.49B 101B 1.51B 10.48B 4.06B 51.67B 3.97B 3.88B 168B
Logo Alvotech
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Employees
1,279
Date Price Change Volume
26-09-24 $5.885 +1.29% 1,197,942
26-09-23 $5.810 -0.51% 774,267
26-09-22 $5.840 -0.68% 978,060
26-09-21 $5.880 +0.17% 1,313,024
26-09-18 $5.870 +9.93% 3,535,735
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
5.885USD
Average target price
6.800USD
Spread / Average Target
+15.55%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALVO Stock